Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda To Develop, Market Novartis Hib Drug In Japan

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceuticals and Novartis have signed a partnership agreement to develop and market a vaccine to prevent meningitis in Japanese children. The vaccine is Novartis' Vaxem-Hib that prevents haemophilus influenza Type B, the lead cause of meningitis and pneumonia. Takeda is to conduct clinical trials in Japan for the vaccine and take the drug through the approval process, marketing it under the Novartis brand name. Takeda is paying Novartis just over $1 million initially, with milestone payments and royalties to follow. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts